Novavax seeks authorization of updated COVID shot in Europe

MarsBars/E+ via Getty Images Novavax ( NASDAQ: NVAX ) has submitted an application to the European Medicines Agency seeking authorization of its JN.1 COVID-19 vaccine to be administered starting in the fall. The shot is also effective against the KP.

2 and KP.3 variants, which alone account for nearly 54% of the cases currently in the U.S.

, according to CDC data . A similar application was submitted to the U.S.

FDA earlier in June. More on Novavax Novavax: New Chapter, Questions Remain Novavax: Bird Flu And COVID-19 Headlines Trigger Rally Novavax, Inc. (NVAX) Jefferies 2024 Global Healthcare Conference (Transcript) Novavax seeks FDA authorization for updated JN.

1 COVID shot FDA recommends KP.2 strain be used in updated COVID-19 shots.